Generic placeholder image

Mini-Reviews in Medicinal Chemistry


ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

Author(s): Michael C. Heinrich

Volume 4, Issue 3, 2004

Page: [255 - 271] Pages: 17

DOI: 10.2174/1389557043487394

Price: $65


Activating mutations of the FLT3 receptor tyrosine kinase are the most common recurring genetic abnormality in acute myelogenous leukemia (AM). Inhibition of FLT3 kinase activity by small molecule inhibitors has been proposed as a novel therapeutic approach AML. The pre-clinical and clinical development of candidate FLT3 inhibitors will be reviewed.

Keywords: flt3, tyrosine kinase, kinase inhibitor, aml, pdgfr

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy